Transmucosal drug delivery devices market set to hit $81.52 billion by 2030

The Business Research Company says the global transmucosal drug delivery devices market will rise from $54.63 billion in 2025 to $59.61 billion in 2026, then reach $81.52 billion by 2030. The report points to chronic disease growth, non-invasive treatment demand and patient-friendly delivery systems as key drivers.

Why it matters: - Transmucosal drug delivery devices are gaining traction because they offer a non-invasive way to deliver medicines through mucous membranes for faster absorption. - The market is tied to chronic disease care, pain management, hormone therapies and broader interest in at-home treatment options. - Growth in this segment signals continued demand for drug delivery methods that improve adherence, dose precision and bioavailability.

What happened: - The Business Research Company published a new report on the transmucosal drug delivery devices market covering 2026 through 2035. - The market is projected to grow from $54.63 billion in 2025 to $59.61 billion in 2026, a 9.1% compound annual growth rate. - The report forecasts the market will reach $81.52 billion by 2030, at an 8.1% CAGR. - The report is available through the company's free sample and full market report. - North America was the largest regional market in 2025.

The details: - Transmucosal drug delivery devices administer medication through the mouth, nasal passages or rectum. - The devices are designed to send drugs directly into the bloodstream for rapid absorption. - They are especially useful for drugs that do not absorb well through the gastrointestinal tract or need a quick therapeutic effect. - The report says growth is being driven by rising use of non-invasive drug delivery methods, pain therapies, hormone replacement therapies and new pharmaceutical formulations. - The forecast also points to personalized medicine, higher investment in advanced delivery technologies, stronger consumer preference for at-home drug administration, a growing pipeline of biologics and peptide-based drugs and regulatory approvals for new systems. - Expected trends include wider use of buccal and sublingual delivery, faster onset, microneedle and active delivery technologies, patient-friendly device designs and better dose precision. - The market coverage also includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report frames transmucosal delivery as part of a broader shift away from traditional oral drug delivery toward faster and more convenient administration methods. - Chronic disease prevalence is a central demand driver because these conditions often require long-term medication and better adherence. - The UK National Health Service reported 3,615,330 patients with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022. - That rise underscores the expanding need for drug delivery tools that support continuous treatment.

What's next: - The report expects the market to keep expanding as more drugs move into biologics, peptide-based therapies and personalized treatment models. - Device makers are likely to focus on improving patient usability, faster onset and more precise dosing. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards and market hotspot infographics.

The bottom line: - Transmucosal drug delivery devices are moving from niche use toward a larger role in chronic care and patient-friendly medicine delivery, with double-digit-sized market gains still ahead.